Resveratrol Promotes Foot Ulcer Size Reduction in Type 2 Diabetes Patients

Author:

Bashmakov Yuriy K.1,Assaad-Khalil Samir H.2,Abou Seif Myriam3,Udumyan Ruzan4,Megallaa Magdy2,Rohoma Kamel H.2,Zeitoun Mohamed2,Petyaev Ivan M.1

Affiliation:

1. Lycotec Ltd, Granta Park, Platinum Building, Cambridge CB21 6GP, UK

2. Department of Internal Medicine, Faculty of Medicine, Alexandria University, Alexandria 21527, Egypt

3. Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria 21527, Egypt

4. Clinical Epidemiology and Biostatistics, Örebro University Hospital and School of Health and Medical Sciences, Örebro University, Örebro, Sweden

Abstract

Objective. The effect of a proprietary formulation of trans-resveratrol (t-RSV) on manifestations of diabetic foot syndrome (DFS) was studied in type 2 diabetic patients with newly diagnosed diabetic foot ulcers. Method. Placebo-controlled, examiner-blinded, parallel-group randomized controlled pilot clinical trial (ACTRN Clinical Trial Registry number 12610000629033) involving 24 patients with DFS (15 males and 9 females, average age of 56.4±9.1 years) divided into the placebo and RSV-treatment groups was performed. 50 mg of t-RSV or placebo capsules was given to each patient twice a day over a 60-day time period. Results. Reduction in the parameters reflecting diabetic ulcer size was more profound in the RSV group as compared to placebo. RSV-treated patients also had a marginally improved performance in the foot pressure test. A statistically significant decline in the plasma fibrinogen level, but not CRP, was also found in the RSV-treated patients. Some improvement in the plasma lipid profile and fasting glucose levels were not related to RSV-treatment, since they have been seen on both the RSV and placebo groups, revealing the effectiveness of medical supervision and education in the newly diagnosed patients with DFS. Conclusion. t-RSV supplementation promotes reduction of the foot ulcer size and reduces plasma fibrinogen level in type 2 diabetic patients.

Publisher

Hindawi Limited

Subject

General Economics, Econometrics and Finance

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3